It is very disturbing that an antibiotic, which is often given out for routine infections, may result in violence, anger toward others, and horribly, may result in suicide-related adverse events.
On Nov. 5th, the true stars of our community took to the podium at the FDA to tell their personal stories. I, along with countless others, were humbled and honored. This meeting represented a huge step in the progress we are making to gain complete recognition of the travesty that the fluoroquinolone class of pharmaceuticals has wrought upon society, to achieve justice for those that have been damaged by these drugs, and to prevent future unnecessary pain and suffering not only for this generation, but for generations to come.
Dr. Beatrice Golomb, University of California San Diego, has been able to successfully publish a paper with four case reports of individuals suffering from Fluoroquinolone Toxicity.
We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.
On August 24th, 2015, members from the FQ community met with staff from the FDA in a third meeting to address the various FDA failures to adequately warn the general public about the true dangers FQ’s pose to the general public, especially our children.
Dr. Miriam J. de Jonge M.D., who herself was floxed has contacted me and asked me to post, what I feel, is a comprehensive and well documented “Dear Colleague” letter, informing other doctors of (FQ) toxicity. It can be used to foster patient/doctor discussions. It is available here to download.
Please help support our fundraising t-shirt campaign, which will provide visual awareness to the eyes of the world, and assist us with operating costs. We have designed a t-shirt to help bring FQ awareness to the general public, but this cannot happen without your assistance.
Why would the FDA make such an outrageous decision to enter into an unprecedented agreement to monitor post-marketing drug surveillance with a private company run by ex-pharmaceutical executives? The FDA would be better off looking at its FAERS data. If they did, they would see drug signals that they have ignored, especially for FQ’s.
Dr. Linda Martin, Dr. Alan Redd, David Melvin, and John Fratti submitted an abstract for the UMDF Symposium on behalf of the FQ community. We are pleased to announce that, after being peer-reviewed by the UMDF Abstract Review Committee, their abstract was selected as a poster for the Symposium.
“The legal and Industry Guidance bars are not too high. The problem is that the FDA has failed to do its job regarding Fluoroquinolone antibiotic safety.”, Dr. Charles Bennett, PharmedOut 2015
On June 10th, 2015 representatives from the Fluoroquinolone community met with Senate Staffers at the Dirksen Senate Building in Washington, D.C. to ensure pressure is maintained on the FDA in regards to updated warnings.
“You can’t do what I do and think the drug companies don’t notice you.” With the media scrutiny and the Citizen Petitions filed over the last year you can bet that Bennett has gotten the attention of some very powerful entities; entities that are going to push back in an effort to silence or undermine our message.
Charles Bennett MD PhD Chair of the Center for Economic Excellence in Medication Safety and Efficacy, Bennett-flashUniversity of South Carolina will be speaking at the PharmedOut’s 5th Annual Conference on June 11-12, 2015 at Georgetown University about Fluoroquinolones..